Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations. Thierry Abribat is a biotech entrepreneur who has founded and managed three biotech companies, one of which, Alizé Pharma 2, was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics (Nasdaq: MLND). Mark Sumeray has 23 years of experience across the pharmaceutical, medical devices and biotech industries, both in the US and EU. Thomas Delale is a biopharmaceutical professional with over 18 years of experience that spans from peptide drug discovery to late clinical stage development and corporate/business development. David has a strong experience working with CMO/CRO and developing product with top pharmaceutical or biotechnologies companies in Europe, US, India and China. Benedicte Gagnere has over 20 years experience in leading financial planning, control & accounting functions and reporting on all international operations. Legault also serves as the chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma.
Écully, France
Founded in 2007
11-50 Employees
Working industry
Biotechnology
Type of company
-
Ownership structure
Privately Held
Locations
2 Locations
Number of products
1 Product
Specialised areas
Therapeutic Peptides, Metabolic Disease, Wellness, Hypoparathyroidism, Pharmaceutical, Therapeutics, Endocrine Disease, Medical, Biotechnology, Rare Disease
Amolyt Pharma offers a wide range of products and services
Product
Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting | Amolyt Pharma
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
France
Overall risk estimation:
Very low
The ESG Data of countries are based on public sources
Environment
A
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Amolyt Pharma operates in 2 countries around the world
Get an overview of the locations of Amolyt Pharma
Location
Country
State
City
Headquarter
France
Auvergne-Rhône-Alpes
Écully
United States Office
United States
Massachusetts
Newton
Some frequent questions that have been asked about Amolyt Pharma
Where is Amolyt Pharma located?
The company headquarter of Amolyt Pharma is located in Écully, Auvergne-Rhône-Alpes, France. Amolyt Pharma has subsidiaries in United States
How many employees does Amolyt Pharma approximately have?
As of the latest available information Amolyt Pharma has around 11-50 employees worldwide.
When was Amolyt Pharma founded?
Amolyt Pharma was founded in 2007
In which industries does Amolyt Pharma mainly work?
The company Amolyt Pharma has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Amolyt Pharma
Esya
Newbury, United Kingdom
1-10 Employees
2018
We are a start-up originally spun out of Dr. Dhivya is a passionate Entrepreneur with 15+ years experience in defining winning strategies and building high performance teams. Vergara has 14+ years of experience in experimental and computational biology. Shellard has a PhD and 12+ years of experience in cell biology and live imaging. Brian brings a track record of leading teams to deliver transformative results for clients across the healthcare sector at McKinsey and Company with particular focus on strategy / corporate finance, go-to-market, and M&A. Laghrissi is the CEO of DalCor Pharmaceuticals and has more than 20 years of pharmaceutical industry leadership experience, including roles at AstraZeneca, Roche, HBA and WPIC. Kupfer is the ex-Head of the DSM-5 plan committee, and has expert knowledge of the current principal manual for psychiatric & neurocognitive diagnosis, as recommended by the American Psychiatric Association. Linder is the CEO at Calciscon AG, biomedical consultant, entrepreneur & senior biotech executive with track record of success for biomedical devices.
Aquros Bio
San Clemente, United States
1-10 Employees
2017
With our extensive combined industry and clinical expertise, our team has track record for identifying novel therapeutic assets and creating value. Aaron Davis 18+ years – Syneos Health, Vertex, Amylin. Soumitra Ghosh, PhD 30+ years – BMS/AZ, Amylin, Mitokor, Baxter Diagnostics, SIBIA. Will Clodfelter 20+ years – Medicus, Amylin/BMS/AZ, Eli Lilly. David Parkes, PhD 20+ years – Gubra, Profil, BMS/AZ, Amylin, Salk.
Fulcrum Therapeutics
Cambridge, United States
51-100 Employees
2016
In addition, we are invested in our people and want to ensure they have the tools and training they need to succeed. We are focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need. We have a culture of trust and transparency which enables our employees to focus on our mission and the science behind it. Patrick Horn brings over 20 years of experience in the field of rare disease drug development, encompassing all stages from initial research to regulatory approval and commercial launch. Jacobs has more than 25 years of experience in drug discovery and target identification, and has led, co-led and mentored multiple discovery programs from concept stage through development candidate nomination, and from investigational new drug enabling studies through to pivotal clinical trials. Jacobs held senior roles in development chemistry at Sunesis Pharmaceuticals, along with similar roles leading chemistry teams at Versicor, Inc. Mel brings more than 30 years of experience in asset development and management of commercialization strategies in a range of therapeutic areas including many rare, specialty and primary care diseases. Katina Dorton joined the Fulcrum Board of Directors in January 2020 and serves as the Chair of the Audit Committee.
Ariana Pharma
Paris, France
11-50 Employees
2003
Dr Commerçon is a former Senior Research Director within the “Lead Generation” organization at Sanofi-Aventis. One of the pioneers of French bioinformatics, Jean is the former Director of the Artificial Intelligence Laboratories at the LIRMM CNRS, Montpellier, France. Former Group CFO of Promethera Biosciences, Bertrand is specialized in innovative companies, with multiple strategical experiences and successful track records.. Former IQVIA Technology & Product Lead, RWE European Oncology network, RiboTargets architect and project manager of RiboDock/rDock. Adam is the CEO of Hyde Park Global Investments is a leading mathematical trading firm based in Atlanta, USA. A serial entrepreneur with a successful track record in multiple industries, Daniel is the CEO of Euracier, a leading company focussed on specialized steel. Ariana Pharma is growing fast, and we are seeking individuals for the following open positions in our Paris office Data Scientist / Biostatisticien(ne) / Biostatistician. Artificial Intelligence and Precision Medicine design leading to accelerated drug development and expedited regulatory approval.
Nimbus Therapeutics
Cambridge, United States
11-50 Employees
2009
Erin has more than 20 years HR leadership experience across biotech, medical device, manufacturing and entertainment industries. Jean is a General Partner of Lightstone Ventures. Mark Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Katharine Knobil has more than 20 years of experience in the pharmaceutical industry including global clinical research, medical affairs, and patient safety across both big pharma and smaller biotechnology companies. Vlasuk is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. George is the author of more than 100 peer-reviewed scientific publications, book chapters and reviews, and 38 issued U.S.
AbolerIS Pharma
Nantes, France
1-10 Employees
2019
Solid scientific results are the foundation of AbolerIS Pharma and will always remain as the driver of the company’s development activities. Ignacio is a co-founder, senior consultant, and member of the SAB of AbolerIS Pharma. Member of several learned scientific societies, Carole coordinates projects leading to the discovery of several therapeutic targets involved in the pathological responses of autoimmune diseases. Francois-Xavier is a co-founder, past president and board member of AbolerIS Pharma. Tomas has more than 30 years of experience in financial management in both big multinationals and small, local companies covering a broad range of industries. Pascal has around 25 years of experience in leading drug discovery and preclinical development programs and teams at several biotech companies. Experience in young biotech companies to develop the strategic development plan for new medicinal products, meetings with investors, and authorities (EMA, FDA, AFMPS), managing CROs and CMOs. Antoine is a CMC expert bringing more than 20 year’s experience acquired in the pharmaceutical industry in the development, manufacturing, clinical supply and regulatory review (FDA, EMA) of several new drugs entities.